In 2013, Brazil’s total pharmaceutical market for type 2 diabetes rivaled the size of some of the major markets. Increasing public awareness, an aging population, and the launch of new premium-priced antidiabetic agents will all contribute to the growth of this market in the next five years. The large, growing prevalent population promises a 7% annual growth in sales and significant opportunity for multinational pharmaceutical companies as demand for branded antidiabetic drugs continues to grow throughout Brazil.

Questions Answered in This Report:

  • As a result of population growth, aging, and trends in obesity, the number of prevalent cases of type 2 diabetes in Brazil will increase over the forecast period. How many prevalent, diagnosed, and drug-treated type 2 diabetes cases were there in Brazil in 2013 and what will those numbers be in 2023? Are men and women equally susceptible to the disease in Brazil? Which age-group is most likely to develop type 2 diabetes in Brazil?

  • Similar to behaviors of U.S. and European physicians, the prescribing patterns of Brazilian endocrinologists and primary care physicians are most influenced by a drug’s efficacy and safety profiles. What other factors drive Brazilian endocrinologists’ and primary care physicians’ prescribing habits? What are interviewed experts’ views of current medical practice and the trends they foresee in the future?

  • The Brazilian type 2 diabetes market is growing more rapidly than those in the United States, Europe, and Japan and is boasting strong annual double-digit growth in sales. Which agents, current and emerging, will be the key players driving market growth over the forecast period? How are the branded drugs expected to fare against generic competitors over the forecast period? Which drugs will dominate the market by 2018?


Primary research: 92 endocrinologist and primary care physician surveys across Brazil. Separate in-depth interviews with 8 medical experts.

Epidemiology: Prevalence of type 2 diabetes in Brazil. Age- and gender-specific ten-year epidemiology forecast (2013-2023).

Market forecast features: Our analysis evaluates the size of the patient population, percentage of diagnosed patients, and percentage of drug-treated patients. We include a detailed forecast for antidiabetic drug classes and leading products from 2013-2018 using a combination of historical trend analysis and an epidemiology-based bottom-up market model.

Author(s): Natalia Reoutova, M.A., M.Sc.
Catherine Vasilakis, Ph.D., M.P.H.

Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details